BioSpace News Archive

Tmunity Therapeutics, Inc., a clinical-stage biotherapeutics company specifically designed to deliver on the bold promise to ‘uncancer the world’ by creating the best T cell medicines for solid tumor patients, today announced the appointment of Jeffrey Leiden, M.D., Ph.D., as Non-Executive Chairman of its Board of Directors.

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced Conformité Européene (CE) mark approval for the CellFX® System.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that three ePosters will be presented at the Maui Derm for Dermatologists 2021 meeting being held in-person at the Grand Wailea in Maui, Hawaii from January 25-29, 2021 and broadcasted via live-stream for those unable to join in person.

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”).

Exelixis, Inc. (NASDAQ: EXEL) today announced initiation of the first-in-human phase 1 trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL102 alone or in combination with other anti-cancer agents in patients with inoperable locally advanced or metastatic solid tumors.

NTT Research, Inc., a division of NTT (TYO:9432), today announced a collaboration to develop a high-speed Coherent Ising Machine (CIM).

Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTF)(“Relief”), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, and Acer Therapeutics today announced that the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license agreement for worldwide development and commercialization for ACER-001.

Theranica , a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio ® therapeutic device has has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.

DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients.

Todos Medical (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced a $3.4 million strategic investment (the “Investment”) from tech-focused venture capital firm Yozma Group Korea (“Yozma”). “Yozma Group Korea is p